Federal contract award
75F40122C00147
PMWP 190 - CDER-2022-112238 ADVANCE THE SCIENCE OF IN VITRO, ANIMAL MODEL, PHARMACOKINETIC STUDIES, AND/OR REAL- WORLD EVIDENCE STUDIES TO FACILITATE DRUG DEVELOPMENT, INCLUDING STUDIES FOCUSED ON ANTIMICROBIAL RESISTANCE AND DRUG DEVELOPMENT FOR SP
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | FDA OFFICE OF ACQ GRANT SVCS |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AN11 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $400.0K |
| Current contract value | $400.0K |
| Potential contract value / ceiling | $400.0K |
| Start date | Sep 26, 2022 |
| Current end date | Mar 31, 2026 |
| Potential end date | Mar 31, 2026 |
| Latest award activity | Jan 8, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 7 of 7 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Jan 8, 2026 | P00006 | $0 | ADVANCING METHODS TO OPTIMIZE ANTIMICROBIAL DOSING IN PATIENTS WITH OBESITY |
| Oct 16, 2025 | P00005 | $0 | ADVANCING METHODS TO OPTIMIZE ANTIMICROBIAL DOSING IN PATIENTS WITH OBESITY |
| Jul 2, 2025 | P00004 | $0 | COR CHANGE |
| Jul 8, 2024 | P00003 | $0 | THE PURPOSE OF THIS MODIFICATION IS A NO COST EXTENSION. |
| May 30, 2023 | P00002 | $0 | THIS IS A MODIFICATION TO REVISE THE POP, SOW AND DELIVERABLES. |
| Dec 15, 2022 | P00001 | $0 | THIS IS A MODIFICATION TO REVISE THE SOW AND DELIVERABLES. |
| Sep 26, 2022 | 0 | $400.0K | PMWP 190 - CDER-2022-112238 ADVANCE THE SCIENCE OF IN VITRO, ANIMAL MODEL, PHARMACOKINETIC STUDIES, AND/OR REAL- WORLD EVIDENCE STUDIES TO FACILITATE DRUG DEVELOPMENT, INCLUDING STUDIES FOCUSED ON ANTIMICROBIAL RESISTANCE AND DRUG DEVELOPMENT FOR SP |
Buyer contacts from matching notices
Matched on exact award/solicitation identifier and awarding agency. Source dates describe the notice, not current contact verification.
| Contact | Role | Published contact methods | Evidence | Source date |
|---|---|---|---|---|
| Robert Maydwell | Contact | Robert.Maydwell@fda.hhs.gov 301-348-1814 | Source | Jan 20, 2022 |
| Terry Frederick | Contact | Terry.Frederick@fda.hhs.gov | Source | Jan 20, 2022 |
| Robert Maydwell | Contact | Robert.Maydwell@fda.hhs.gov 301-348-1814 | Source | Jan 7, 2022 |
| Terry Frederick | Contact | Terry.Frederick@fda.hhs.gov | Source | Jan 7, 2022 |
| Robert Maydwell | Contact | Robert.Maydwell@fda.hhs.gov 301-348-1814 | Source | Jan 7, 2022 |
| Terry Frederick | Contact | Terry.Frederick@fda.hhs.gov 301-348-1814 | Source | Jan 7, 2022 |
| Robert Maydwell | Contact | Robert.Maydwell@fda.hhs.gov 301-348-1814 | Source | Nov 10, 2021 |
| Kimberly DeLong | Contact | kimberly.delong@fda.hhs.gov 240-402-8639 | Source | Nov 10, 2021 |
| Robert Maydwell | Contact | Robert.Maydwell@fda.hhs.gov 301-348-1814 | Source | Nov 10, 2021 |
| Kimberly DeLong | Contact | kimberly.delong@fda.hhs.gov 240-402-8639 | Source | Nov 10, 2021 |
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.